Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Asher Biotherapeutics logo — Asher Bio is a biotechnology company developing precisely ta...

Asher Biotherapeutics

Asher Bio is a biotechnology company developing precisely targeted immunotherapies for cancer and other diseases.

Founded 2019 United States South San Francisco, United States 15 employees Series C Total: $218.13M Biotechnology, Health and Wellness

General Information

Company Name Asher Biotherapeutics
Founded Year 2019
Location United States South San Francisco, United States +1
Employees 15
Industries Biotechnology, Health and Wellness
Funding Stage Series C
Social

Get notified when Asher Biotherapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Asher Biotherapeutics

Asher Biotherapeutics is a biotechnology company founded in 2019 and based in South San Francisco, United States. The company's slogan "Asher Bio is a biotechnology company developing precisely targeted immunotherapies for cancer and other diseases" reflects its focus on developing precisely targeted immunotherapies for cancer and other diseases. Asher Bio's last investment was a significant $108.00M Series B investment on 01 September 2021. This investment round was supported by a notable group of investors including RA Capital Management, Third Rock Ventures, Boxer Capital, Invus, Marshall Wace, Wellington Management, Alexandria Venture Investments, Janus Handerson, Logos Capital, and Mission BioCapital. The company's proprietary cis-targeting platform aims to enable selective activation of specific immune cell types, potentially addressing the limitations of pleiotropic immunotherapies that act on multiple cell types. This innovative approach has the potential to precisely direct different immune mediators against a range of target immune cell-types, creating potential best-in-class immunotherapies in cancer, autoimmune, and infectious diseases. Overall, Asher Biotherapeutics, with its innovative approach and strong backing from renowned investors, is well-positioned to make a meaningful impact in the field of targeted immunotherapies for various diseases.

Taxonomy: immunotherapy, cancer research, immune cell targeting, oncology, autoimmune diseases, infectious diseases, precise medicine, South San Francisco, Third Rock Ventures, startup, San Francisco, CFO Office transformation, information technology

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Series C •••••• 7
Investor Investor Investor Investor Investor Investor
•••• •••• 		01 Apr 2024
Series B •••••• 10
Investor Investor Investor Investor Investor Investor Investor Investor Investor Investor
01 Sep 2021
Series A •••••• 5
Investor Investor Investor Investor Investor
01 Mar 2021
Seed •••••• 1
Investor
01 Sep 2019

Asher Biotherapeutics Alternatives & Competitors

Asher Biotherapeutics vs
revimmune
revimmune

Comprehensive T-cell support and advanced immune therapies for treating complex immune disorders.

5 employees
Manufacturing
Asher Biotherapeutics vs
Sonoma Biotherapeutics, Inc.
Sonoma Biotherapeutics, Inc. United States

Leading the Next Frontier of Cell Therapy

Corporate Round
65 employees
Biotechnology, Health and Wellness
Asher Biotherapeutics vs
Deverra Therapeutics
Deverra Therapeutics United States

Cell Therapies for All

Grant
14 employees
Biotechnology

FAQ About Asher Biotherapeutics

Asher Bio is a biotechnology company developing precisely targeted immunotherapies for cancer and other diseases.
Asher Biotherapeutics was founded in 2019.
Asher Biotherapeutics is headquartered in South San Francisco, United States.
Asher Biotherapeutics operates in the following industries: Biotechnology, Health and Wellness.
Asher Biotherapeutics has approximately 15 employees.
Asher Biotherapeutics has completed 4 funding rounds, raising a total of $218.13M. The latest funding stage is Series C.
Top alternatives and competitors to Asher Biotherapeutics include revimmune , Sonoma Biotherapeutics, Inc., Deverra Therapeutics, SQZ Biotechnologies, Sedec Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Asher Biotherapeutics and revimmune are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Asher Biotherapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes